BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · Real-Time Price · USD
0.341
+0.026 (8.12%)
At close: Dec 20, 2024, 4:00 PM
0.342
+0.001 (0.26%)
After-hours: Dec 20, 2024, 7:10 PM EST
8.12%
Market Cap 14.58M
Revenue (ttm) 2.28M
Net Income (ttm) -71.00M
Shares Out 42.75M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 822,140
Open 0.302
Previous Close 0.315
Day's Range 0.300 - 0.344
52-Week Range 0.300 - 4.170
Beta -0.03
Analysts Strong Buy
Price Target 5.00 (+1,366.28%)
Earnings Date Nov 14, 2024

About BTAI

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation as... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 74
Stock Exchange NASDAQ
Ticker Symbol BTAI
Full Company Profile

Financial Performance

In 2023, BioXcel Therapeutics's revenue was $1.38 million, an increase of 268.00% compared to the previous year's $375,000. Losses were -$179.05 million, 8.02% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 1,366.28% from the latest price.

Price Target
$5.0
(1,366.28% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

4 weeks ago - GlobeNewsWire

BioXcel Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

4 weeks ago - GlobeNewsWire

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial O...

5 weeks ago - Seeking Alpha

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...

6 weeks ago - GlobeNewsWire

BioXcel Therapeutics to Present at ThinkEquity Conference

NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...

7 weeks ago - GlobeNewsWire

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 ~ 40 million Americans go to emergency department annually after a traumatic experience 1 Second externally funded stress-r...

2 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia

3 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

E stimated 23 million annual agitation episodes in the at-home setting 1-3   No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders or schi...

3 months ago - GlobeNewsWire

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Vincent O'Neill - Executive Vi...

4 months ago - Seeking Alpha

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch

5 months ago - GlobeNewsWire

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuro...

7 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuro...

7 months ago - GlobeNewsWire

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Results Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer and Founder Vincent O'Neill - Execu...

8 months ago - Seeking Alpha

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation

8 months ago - GlobeNewsWire

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neu...

8 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE...

8 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA

8 months ago - GlobeNewsWire

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) -- BioX...

9 months ago - GlobeNewsWire

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

9 months ago - GlobeNewsWire

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Newly granted patent aligns with Company's focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 Newly granted patent aligns with Company's focus on exp...

10 months ago - GlobeNewsWire

BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Conference Call March 12, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Vince O'Neill - Chief of Product and Dev...

10 months ago - Seeking Alpha

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY pro...

10 months ago - GlobeNewsWire

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neu...

10 months ago - GlobeNewsWire

BioXcel Therapeutics Announces Termination of Proposed Public Offering

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur...

11 months ago - GlobeNewsWire

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability

11 months ago - GlobeNewsWire